Innate immune myeloid cells, such as monocytes and macrophages, are crucial effectors and regulators of inflammation, and they are also involved in the maintenance of tissue homeostasis. 1 In response to inflammatory signals (eg, bacterial infection 2 ), circulating monocytes extravasate and reach inflamed tissues, where they terminally differentiate into macrophages. Monocyte-to-macrophage differentiation can be recapitulated in vitro by exposing cells to GM-CSF or macrophage colonystimulating factor (M-CSF), 3 with in vitro-differentiated GM-CSF-exposed macrophages producing larger amounts of proinflammatory cytokines than M-CSF-exposed macrophages. Moreover, monocytes themselves can respond to inflammatory cytokines, such as IL-1b, which promote their activation.
A crucial component of the monocyte/macrophage defense against microbial pathogens and endogenous danger signals is the inflammasome. Inflammasomes are multimeric complexes that assemble in the cytosol after sensing pathogens or dangerassociated molecular patterns (eg, endogenous ATP or uric acid). 4 Once assembled, the inflammasome recruits and activates caspase-1 (CASP-1) and is thereby able to produce active forms of IL-1b and IL-18, inducing an inflammatory form of cell death known as pyroptosis. 5 Inflammasomes consist of a sensor molecule, an adaptor molecule, and the effector molecule CASP-1. The sensor molecules are either members of the NOD-like receptor (NLR) family or the absent in melanoma 2 (AIM2)-like receptor family. 4 The adaptor molecule apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC; encoded by PYCARD) contains specific domains needed for a proper interaction between sensor molecules and CASP-1. Once activated by the inflammasome, CASP-1 cleaves different inflammatory proteins (IL-1b, IL-18, and IL-33) into their bioactive forms. 6 Related to these molecules, the IL-1 receptor antagonist (encoded by IL1RN) is a potent anti-inflammatory molecule that competes with IL-1a and IL-1b for IL-1 receptor binding.
The most extensively studied inflammasome is formed after oligomerization of NLRP3, ASC, and pro-CASP-1. Gain-offunction mutations in the NLRP3 gene, also known as the coldinduced autoinflammatory syndrome 1 (CIAS1) gene, cause cryopyrin-associated periodic syndromes (CAPS). This monogenic autoinflammatory disease includes 3 phenotypes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. Autoinflammatory diseases are characterized by periodic or chronic episodes of systemic inflammatory attacks in the absence of infection or autoimmune disease. Currently, more than 20 genes have been found to be associated with different monogenic autoinflammatory diseases, 7 including the MEFV gene, which encodes the pyrin protein that is mutated in familial Mediterranean fever (FMF), and the PSTPIP1 gene, which is mutated in patients with pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome.
Despite the well-established genetic nature of these diseases, their penetrance varies, probably as a consequence of factors beyond the specific genetic defect. This is exemplified by the fact that autoinflammatory diseases can develop in adults, who are generally characterized by milder clinical features and higher frequency of low-penetrance mutations than pediatric patients. 8 It is likely that epigenetic alterations contribute to the pathogenesis and final clinical phenotype of these diseases.
Epigenetic marks, including methylation at cytosines followed by guanines (CpGs) and histone posttranslational modifications, are associated with gene expression status. Epigenetic changes are essential in cell differentiation. Specifically, genes relevant to macrophage function become demethylated (and overexpressed) during monocyte-to-macrophage differentiation. 9 By re-examining data from our previous study (GEO Series accession no. GSE71837), 10 we found that several inflammasome-related genes demethylate during monocyte-tomacrophage differentiation, which suggests that DNA methylation has a relationship with their transcriptional status. For this reason, we hypothesized that these genes display an aberrant methylation status in monocytes and macrophages of patients with autoinflammatory diseases compared with those from healthy subjects. The present study investigated whether these regulatory marks were altered in the context of these diseases.
METHODS

Isolation of peripheral blood monocytes and differentiation and activation experiments
Human blood samples from healthy control subjects were obtained as buffy coats from the Catalan Blood and Tissue Bank (CBTB). Anonymous healthy donors received oral and written information about the possibility that their blood would be used for research purposes. Before obtaining the first blood sample, all donors signed a consent form at the CBTB. The CBTB follows the principles set out in the World Medical Association Declaration of Helsinki. Blood samples corresponding to patients with CAPS and those with FMF came from Hospital Cl ınic, Hospital Vall d'Hebron and Hospital Universitari Germans Trias i Pujol in Barcelona. Participating clinicians gained approval from their corresponding ethics committees, and patients provided signed informed consent.
PBMCs were isolated by using a Ficoll-Paque gradient (Amersham, Buckinghamshire, United Kingdom). Pure monocytes were isolated from PBMCs by using positive selection with MACS magnetic CD14 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were then resuspended in RPMI 1640 (13) plus GlutaMAXTM-1 (Gibco, Life Technologies, Carlsbad, Calif) containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. For macrophage differentiation, medium was supplemented with 800 U of GM-CSF (Gentaur Molecular Products, Kampenhout, Belgium) over the course of 4 days and activated with 1 mg/mL LPS (Sigma-Aldrich, St Louis, Mo) for 24 hours. Monocytes were also activated either with LPS (1 mg/mL, Sigma-Aldrich) or IL-1b (10 ng/mL; PeproTech, Rocky Hill, NJ), and samples were harvested at various time points between 0 and 24 hours.
Bisulfite sequencing and pyrosequencing
Bisulfite modification of genomic DNA isolated from monocytes and macrophages was performed by using standard methods with biological triplicates. Oxidative bisulfite modifications were performed, as described by Booth et al. 11 Briefly, 2 mL of the converted DNA (approximately 20-30 ng) was used as a template in each subsequent PCR. Primers for PCR amplification and sequencing were designed with the PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany). PCRs were performed with the HotStart Taq DNA polymerase PCR kit (Qiagen), and the success of amplification was assessed by means of agarose gel electrophoresis. PCR products were pyrosequenced with the PyroMark Q24 system (Qiagen). Primer sequences are listed in Table E1 in this article's Online Repository at www.jacionline.org.
Quantitative real-time PCR
For quantitative real-time PCR (qRT-PCR), cDNA was produced with SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, Calif). qRT-PCR was done on a LightCycler 480 II System using LightCycler 480 SYBR Green Mix (Roche, Basel, Switzerland). Reactions were carried out in triplicate, and qRT-PCR data were analyzed by using the standard curve method. Data were normalized against the housekeeping genes ribosomal protein L38 (RPL38) and hypoxanthine phosphoribosyltransferase 1 (HPRT1), which were used as controls. Primer sequences are listed in Table E1 . 
Transfection of primary human monocytes
We used ON-TARGETplus small interfering RNAs (siRNAs) against Tet methylcytosine dioxygenase 2 (TET2) to perform knockdown experiments in peripheral blood monocytes. We also used the ON-TARGETplus Non-targeting Control Pool as a negative control. We transfected monocytes with siRNAs using Lipofectamine 3000 Reagent (Thermo Fisher Scientific, Carlsbad, Calif) and added 800 U of GM-CSF (Gentaur Molecular Products) 24 hours later. We examined TET2 levels by using Western blotting (reference: MABE462; Millipore, Billerica, Mass) 4 days after GM-CSF addition (5 days after transfection).
Putative binding of nuclear factor kB motifs
The possible occurrence of nuclear factor kB (NF-kB) subunit binding motifs in the region comprising 1500 bp around the transcription start site was inspected by using ConSite matrices.
Chromatin immunoprecipitation assays
For chromatin immunoprecipitation (ChIP) assays, CD14
1 cells (monocytes) treated with GM-CSF, IL-1b, or LPS at various time points between 0 and 24 hours were crosslinked with 1% formaldehyde over 15 minutes and subjected to immunoprecipitation after sonication by using a Covaris ultrasonicator (Covaris, Woburn, Mass). ChIP experiments were performed with the low-cell ChIP kit protein A (Diagenode SA, Seraing, Belgium). We used a rabbit polyclonal antibody against the carboxyl-terminal end of NF-kB p65 (sc-372; Santa Cruz Biotechnology, Heidelberg, Germany).
Immunoprecipitated material was used to analyze specific sequences by using qRT-PCR (see primer sequences in Table E1 ).
Apoptosis assay
To quantitate apoptosis, we used the fluorescein isothiocyanate Annexin V Apoptosis Detection Kit II (BD Biosciences, San Jose, Calif). Monocytes were cultured with GM-CSF, IL-1b, or LPS alone or in combination with monosodium urate (MSU) crystals and ATP over 24 hours. As a positive control, monocytes were cultured with 10 mmol/L camptothecin for 4 hours. Approximately 1 3 10 6 cells/mL were stained with Annexin V conjugated with fluorescein isothiocyanate and propidium iodide and processed on a Gallios Flow Cytometer (Beckman Coulter, Pasadena, Calif) and subsequently analyzed by using FlowJo software (Tree Star, Ashland, Ore).
Cytokine detection
Supernatants from 24-hour LPS-activated GM-CSF-exposed macrophages were collected, and IL-1b, IL-6, IL-8, and TNF-a levels were measured by using the Cytokine Human Ultrasensitive MultiPlex Panel for Luminex Platform (Thermo Fisher Scientific), according to the manufacturer's instructions.
Statistical analysis
Statistical significance of the differences in methylation levels of healthy control subjects and patients with CAPS or those with FMF was evaluated by using the paired t test (for direct comparison of methylation percentages between monocytes before/after stimulation) and Mann-Whitney U test (for the comparison of ratios between healthy control subjects vs patients with CAPS or those with FMF at the indicated conditions; GraphPad Prism 6; GraphPad Software, La Jolla, Calif). Differences were considered significant at a P value less than .05.
RESULTS
DNA demethylation signature of inflammasomeassociated genes during monocyte-to-macrophage differentiation
The examination of DNA methylation changes in primary human monocyte-to-macrophage GM-CSF-mediated differentiation (followed by LPS-mediated activation) revealed loss of methylation at thousands of CpG sites (GSE71837). 10 Among the functional categories significantly enriched when performing gene ontology analysis of the demethylated CpG sites, we identified several categories relevant to macrophage identity and function (inflammatory response [GO:0006954], P 5 8.1e-08; innate immune response [GO:0045087], P 5 7.8e-08). Specifically, we identified within these categories several genes related to the inflammasome (AIM2, NLRC5, PYCARD, CASP1, and PSTPIP2) or its targets (IL1A, IL1B, and IL1RN; Fig 1, A, top; GSE71837), for which demethylation was accompanied by subsequent activation of gene expression (Fig 1, A, bottom; GSE75938). Bisulfite pyrosequencing of these CpG sites during monocyte-to-macrophage differentiation confirmed these changes over time (Fig 1, B) . In some cases, such as with IL1B, changes were very fast, and greater than 80% demethylation occurred within 24 hours after exposure to GM-CSF (Fig 1, B) . Other genes (IL1RN, NLRC5, and AIM2) displayed more gradual methylation changes. In these analyses we included control genes that did not become demethylated during monocyte-to-macrophage differentiation, such as DUOX1.
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In parallel, we also checked expression changes of these inflammasome-associated genes over time. Several genes, including IL1A, IL1B, AIM2, and NLRC5, underwent an increase in mRNA levels but only after LPS-mediated activation, whereas others (IL1RN and PSTPIP2) were concomitantly activated as demethylation progressed (Fig 1, B) .
To further explore how increased expression of these genes depends on DNA demethylation, we downregulated TET2. TET2 participates in active demethylation in monocytes 12 through the generation of oxidized intermediates of 5-metylcytosine, such as 5-hydroxymethylcytosine (5hmC). Therefore we performed siRNA experiments to obtain efficient downregulation of TET2 (Fig 1, C) and tested the effects on the demethylation and upregulation of inflammasome genes using DUOX1 as a control gene. We observed partial impairment of demethylation after TET2 depletion (Fig 1, D) . Accumulation of 5hmC, which occurs on monocyte stimulation with GM-CSF, also decreased after TET2 downregulation (Fig 1, D) . Analysis of the mRNA levels of these genes by using qRT-PCR showed that downregulation of TET2 also resulted in decreased upregulation (Fig 1, E) , revealing that inflammasome-associated genes depend on TET2-mediated demethylation for activation.
Finally, we performed Luminex assays to measure the levels of inflammatory cytokine IL-1b released into the medium on LPS activation of macrophages and to test the effects of TET2 downregulation. Our results showed a dependence on TET2 in (TSS; red arrow) and the CpG site location (below) is included. C, qRT-PCR and Western blotting showing the effective downregulation of TET2 in monocytes at 96 hours. D, Analysis of 5-methylcytosine (5mC; top) and 5hmC (bottom) levels in TET2 siRNA-silenced immature macrophages performed by using combination of DNA bisulfite and oxidative bisulfite techniques (bisulfite 5 5mC 1 5hmC, oxidative bisulfite 5 5mC) 5 days after transfection. E, qRT-PCR of inflammasome genes in siRNA-silenced TET2 immature macrophages. F, Cytokine levels after siRNA-mediated silencing of TET2 measured by using the Luminex assay. iMAC, Immature macrophage; mMACs, mature macrophage; MO, monocyte. *P < .05. = J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 the ability of GM-CSF-exposed macrophages to produce and secrete bioactive IL-1b directly linked to TET2 levels (Fig 1, F) , although other measured cytokines showed different behavior (TNF-a increased production after TET2 inhibition, and no changes of IL-8 secretion were detected).
Direct stimulation of the inflammasome in monocytes results in active demethylation of IL1B, IL1RN, and CASP1
Our results demonstrated that expression of several inflammasome genes depends on TET2-mediated DNA demethylation in GM-CSF-mediated monocyte-to-macrophage differentiation. This prompted us to evaluate demethylation of such genes in monocytes exposed to inflammatory conditions. To this end, we compared the DNA methylation changes in monocytes under exposure to IL-1b (10 ng/mL) and LPS (1000 ng/mL) over a period of 24 hours. We used LPS alone; in combination with NLRP3 inflammasome inducers, such as MSU crystals (200 ng/mL) 13 ; or in the presence of ATP (1 mmol/L).
14 These conditions were compared with the exposure of monocytes to GM-CSF. Given that monocytes spontaneously attach to culture plates and differentiate to macrophages, even in the absence of stimulation, we also performed parallel experiments to test all the above conditions in the presence of poly-2-hydroxyethyl methacrylate to minimize the adherence of monocytes to the plates.
To test whether these conditions induce apoptosis or necrosis, we performed flow cytometric analysis using Annexin V and propidium iodide staining, with exposure to camptothecin as a positive control of apoptosis (Fig 2, A) . We observed that GM-CSF and IL-1b did not stimulate apoptosis.
After exposure of monocytes to these different stimuli, we performed bisulfite pyrosequencing and qRT-PCR of inflammasome-associated genes. As controls, we also analyzed DUOX1 and MITF, genes that undergo demethylation during monocyte-to-macrophage differentiation but are not linked to inflammation. Both LPS and IL-1b stimulation resulted in demethylation of inflammasome-associated genes, such as IL1B, IL1A, IL1RN, and CASP1, over a 24-hour period (Fig 2, B) . Our results were consistent with the ability of MSU crystals to enhance the LPS-induced release of IL-1b by monocytes through a CASP-1-mediated process. 15 Demethylation associated with IL-1b or LPS stimulation only affected inflammasome genes (Fig 2, B) . We obtained similar results with monocytes exposed to IL-1b in the presence of poly-2-hydroxyethyl methacrylate, which prevented the attachment of monocytes to the culture plates (see Fig E1, A, in this article's Online Repository at www.jacionline. org). Direct stimulation of monocytes was associated with a peak of increased mRNA levels around 3 to 6 hours after stimulation (Fig 2, C) for inflammasome-associated genes, such as IL1A, IL1B, IL1RN, and CASP1, whereas control genes (DUOX1 or MITF) displayed different expression dynamics. In the case of genes such as IL1A and IL1RN, this peak in expression coincided with an increase in 5hmC levels (see Fig E1, B) . Other genes, such as AIM2 and PYCARD, did not display an increase in mRNA levels during the first 24 hours (see Fig E1, C) , suggesting alternative mechanisms for these 2 genes under LPSand IL-1b-mediated monocyte activation.
We also observed that camptothecin-induced apoptosis did not result in demethylation of inflammasome-associated genes, such as IL1B or AIM2 (see Fig E1, D) , reinforcing the notion that the observed demethylation is independent of apoptosis.
NF-kB mediates demethylation of inflammasomeassociated genes
Toll-like receptor-or IL-1 receptor-initiated signals are known to generate strong NF-kB-mediated responses in monocytes and macrophages. Analysis of the sequences in a 1500-bp window around the transcription start site of inflammasome-associated demethylated genes showed the presence of NF-kB p65 subunit binding sites (Fig 3, A) . To investigate the involvement of NF-kB in the DNA demethylation process affecting inflammasome genes, we first treated monocytes with the NF-kB inhibitor Bay 11-7082 and investigated its effects on the DNA methylation changes of inflammasome-associated genes under different conditions (GM-CSF, IL-1b, and LPS in the absence or presence of MSU and ATP). Bay 11-7082 reduces the levels of phosphorylated Ser536 of p65, which corresponds to its active form. We tested concentrations similar to those previously used 16 and selected 10 mmol/L for Bay 11-7082. The phosphorylation of p65 observed after IL-1b or LPS stimulation of monocytes decreased in the presence of Bay 11-7082 (Fig 3,  B) . We then performed bisulfite pyrosequencing to measure the effects of this NF-kB inhibitor on the DNA methylation levels of inflammasome-associated genes. Bay 11-7082 dramatically impaired DNA demethylation in all cases (Fig 3, C) . Control genes not associated with inflammation, such as DUOX1, did not show any effect (Fig 3, C) . These effects were also noted at the expression level (Fig 3, D) .
To test the potential direct effect of NF-kB on these methylation changes, we performed ChIP assays to assess the binding of NF-kB subunit p65 to inflammasome genes. We confirmed the specific binding of NF-kB p65 to genes, such as IL1B, IL1A, IL1RN, and CASP1 (and the absence of binding to unrelated control genes, such as the myogenic regulatory gene MYOD1; Fig 3, E) , after stimulation with IL-1b and LPS, reinforcing the notion that NF-kB participates in their regulation.
Patients with CAPS not treated with anti-IL-1 drugs are more prone to demethylation of inflammasome genes than healthy control subjects and treated patients
The ability of inflammasome-associated genes to demethylate and activate provides a potential mechanism that could be dysregulated under certain conditions, such as monogenic autoinflammatory diseases, including CAPS and FMF.
Therefore we examined the demethylation of inflammasomerelated genes in monocytes to macrophages after stimulation by GM-CSF under the aforementioned inflammatory conditions in the presence of IL-1b in a small cohort of patients with CAPS (n 5 17), patients with FMF (n 5 5), and healthy control subjects (n 5 21). Patients with CAPS and FMF displayed bona fide mutations (see Table E2 in this article's Online Repository at www.jacionline.org). For the group of patients with CAPS, 5 of 17 patients had not received anti-IL-1 treatment.
We observed that unstimulated monocytes from patients and healthy control subjects displayed virtually identical levels of DNA methylation for IL1B, ILR1N, NLRC5, AIM2, PYCARD, and CASP1 (Fig 4 and at www.jacionline.org). However, we found that monocytes stimulated with IL-1b underwent significantly more efficient demethylation of IL1B, IL1RN, NLRC5, and PYCARD in patients with CAPS who had not been treated with anti-IL-1 therapy than in healthy control subjects (Fig 4) . Patients with CAPS who received anti-IL-1 treatment did not display significant differences when compared with healthy control subjects, suggesting that the treatment might reverse the trend observed for patients with CAPS in the absence of such therapy. This trend was also apparent for monocytes stimulated with GM-CSF for 24 hours, although the comparison was only significant for the IL1B gene (see Fig E2, A, in this article's Online Repository at www.jacionline.org). In the case of patients with FMF, the results did not reach statistical significance, and no evident differences were observed (see Fig E2, B) . To test whether the difference in untreated patients with CAPS was associated with differential upregulation of these genes, we performed qRT-PCR to quantitate their mRNA levels. We observed a trend for increased expression gene is indicated on the left, and the treatments (LPS, IL-1b, and GM-CSF) are shown at the top of each graph. Heat maps for each treatment (LPS, IL-1b, and GM-CSF) summarizing methylation levels of genes at 12 and 24 hours of stimuli are depicted. D, Gains of gene expression for inflammasome-associated genes in the absence or presence of the NF-kB inhibitor Bay 11-7082, as analyzed by using qRT-PCR in monocytes cultured under previously described conditions. E, ChIP assays showing binding to indicated genes of the NF-kB p65 at 0, 3, 12, and 24 hours after stimulation of monocytes with IL-1b, LPS, and GM-CSF. Data are presented as relative enrichment (immunoprecipitated fraction divided by the input fraction). The MYOD1 gene is used as a control gene. *P < .05. Tables E2 and E3 ). The Mann-Whitney U and paired t tests were used for comparisons (as specified in the Methods section). *P < .05, **P < .01, ***P < .001, and ****P < .0001. n.s., Not significant.
of genes, such as IL1B and IL1RN, in untreated patients with CAPS compared with healthy subjects and patients with CAPS treated with anti-IL-1b therapy, although the data did not reach statistical difference (see Fig E2, C) at 24 hours. However, we cannot discard the possibility that differences can occur under different dynamics than those obtained for DNA methylation. In summary, our results indicate that stimulated monocytes from patients with CAPS have lower methylation levels for several inflammasome-related genes than their healthy counterparts and that IL-1 drugs could reverse that trend.
DISCUSSION
For the first time, our results identify the existence of TET2-dependent DNA demethylation for several inflammasome-related genes in monocyte-to-macrophage differentiation and monocytes under inflammatory conditions. The capacity of inflammasomerelated genes to become demethylated is also dependent on NF-kB. We also report that the DNA methylation-dependent regulation of inflammasome product genes, notably IL1B, IL1RN, NLRC5, and PYCARD, is exacerbated in patients with CAPS who do not receive anti-IL-1 drugs and that treatment reverses such an effect, providing a potential source for useful clinical biomarkers.
Our study reports the relationship between DNA demethylation and upregulation of inflammasome-related genes in monocyte-tomacrophage differentiation and on direct Toll-like receptor-or IL-1 receptor-mediated stimulation of monocytes. In the case of GM-CSF-mediated monocyte-to-macrophage differentiation, genes like IL1B, IL1A, NLRC5, AIM2, and CASP1 display DNA demethylation during the differentiation step before their increase in expression, which occurs only after LPS-mediated activation of macrophages. This suggests that DNA demethylation is a first and required step to guarantee the proper and fast response of the inflammasome. DNA demethylation is TET2 dependent, as demonstrated by the partial impairment of DNA demethylation and upregulation of gene expression and proper inflammasomemediated response after TET2 downregulation, thus indicating the relevance of active DNA demethylation during the process.
In addition to demethylation during GM-CSF-stimulated monocyte-to-macrophage differentiation, inflammasome-related genes also become demethylated when monocytes are directly stimulated with LPS and IL-1b. Under these conditions, the dynamics of expression in relation to DNA demethylation vary with respect to the GM-CSF conditions, suggesting the participation of additional players, coexistent mechanisms, or both in the regulation of these genes.
Our results also confirm the involvement of NF-kB in DNA demethylation and the upregulation of inflammasome-related genes during monocyte activation. NF-kB can participate directly or indirectly in the recruitment of TET2, resulting in subsequent DNA demethylation. Additional experiments to explore the potential interaction between NF-kB subunits and TET2 are needed.
Finally, we have found that exacerbated DNA demethylation of several inflammasome-related genes (IL1B, IL1RN, NLRC5, and PYCARD) occurs in activated monocytes from untreated patients with CAPS compared with their healthy counterparts. DNA demethylation in patients with CAPS could set a lower threshold for IL-1b production, establishing a positive loop between IL-1b production and further inflammasome activation. Nonetheless, no basal differences in DNA methylation of the inflammasomerelated genes are apparent in nonstimulated monocytes when comparing patients and healthy control subjects, and only IL-1b stimulation is capable of unveiling the difference between them. Thus high IL-1b levels would recapitulate the natural environment of monocytes in these IL-1b-driven diseases, enhancing DNA demethylation in patients with CAPS and causing a major induction of gene expression relative to control subjects.
In this study untreated patients with CAPS harboring different mutations (see Table E2 ) exhibited a similar methylation profile of IL-1b-stimulated monocytes in genes, such as IL1B, ILR1N, NLRC5, and PYCARD. These findings suggest that defects in the epigenetic control of these genes are independent of the specific mutation of the NLRP3 gene, and perhaps enhanced demethylation is present in symptomatic patients who do not meet the genetic diagnostic criteria. In this sense the generation of high-throughput profiles of DNA methylation for these patients could provide further insight into the extent of methylationrelated defects in patients with CAPS and evaluate the potential for additional diagnostic markers. It is remarkable that patients with CAPS undergoing anti-IL-1b treatment display demethylation levels in stimulated monocytes similar to those seen in healthy control subjects, suggesting the effectiveness of the drug in preventing the exacerbated demethylation of inflammasome-related genes that occurs in the absence of such therapy.
In summary, our study suggests the existence of a DNA methylation-mediated control of inflammasome-related genes in monocytes that could contribute to a quick response in an inflammatory environment. These changes are exacerbated in the context of an IL-1b-mediated monogenic autoinflammatory disease, specifically CAPS, perhaps participating in its phenotypic development. Our results highlight the need to further explore these mechanisms and the feasibility of using these epigenetic events as additional biomarkers in the context of autoinflammation.
Key messages
d Inflammasome-related genes undergo demethylation during macrophage differentiation and monocyte activation.
d Demethylation and upregulation of inflammasome genes depends on both TET2 and NF-kB.
d Demethylation of inflammasome genes is exacerbated in patients with CAPS, an effect not observed in those patients with CAPS who are treated with anti-IL-1 drugs. 
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Ratio 24h / 0h C ** **** **** ** **** **** * *** **** ** **** **** **** n.s. *** **** n.s. * Tables E2 and E3 ). B, Methylation levels of monocytes from patients with FMF versus healthy subjects before (0 hours) and after (24 hours) stimulation with GM-CSF or IL-1b, as estimated by using bisulfite pyrosequencing. For each gene, the ratio between the methylation percentage of monocytes at 24 hours after stimulation and before stimulation is represented. C, Expression data: qRT-PCR for patients with CAPS (untreated/treated with anti-IL-1b drugs) versus healthy subjects. *P < .05, **P < .01, ***P < .001, and ****P < .0001. 
